8-K: Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI in Germany

Fennec Pharmaceuticals' partner, Norgine Pharmaceuticals, has launched PEDMARQSI in Germany, marking a significant step in the global commercialization of the drug for preventing cisplatin-induced ototoxicity.

Summary

• Fennec Pharmaceuticals announced that Norgine Pharmaceuticals has commercially launched PEDMARQSI (sodium thiosulfate injection) in Germany on February 7, 2025.
• PEDMARQSI is the first and only approved therapy in the EU and U.K. for preventing ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients aged 1 month to under 18 years with localized, non-metastatic solid tumors.
• Fennec received approximately $43 million upfront from Norgine and is eligible for up to approximately $230 million in additional commercial and regulatory milestone payments, plus double-digit tiered royalties on net sales.
• Clinical trials (SIOPEL 6 and COG Protocol ACCL0431) showed an approximate 50% reduction in cisplatin-induced ototoxicity in patients treated with cisplatin and sodium thiosulfate versus cisplatin alone.
• PEDMARQSI was granted marketing authorization by the European Commission in June 2023 under the paediatric-use marketing authorization (PUMA), providing 8 years plus 2 years of data and market protection.

Sentiment

Score: 8

Explanation: The announcement is positive due to the commercial launch of a key product, potential revenue streams from milestone payments and royalties, and the drug's unique position in the market. However, inherent risks in the pharmaceutical industry and forward-looking statements temper the overall sentiment.

Positives

• Commercial launch of PEDMARQSI in Germany represents a significant step in expanding access to the drug.
• PEDMARQSI is the first and only approved therapy for its indication in the EU and U.K.
• The licensing agreement with Norgine provides Fennec with substantial upfront and potential milestone payments, as well as royalties.
• Clinical trial data supports the efficacy of PEDMARQSI in reducing cisplatin-induced ototoxicity.
• Marketing authorization provides market exclusivity for PEDMARQSI in Europe.

Risks

• Regulatory and guideline developments may change.
• Scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals.
• Clinical results may not be replicated in actual patient settings.
• Unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak.
• Protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors.
• The available market for the Company's products will not be as large as expected.
• The Company's products will not be able to penetrate one or more targeted markets.
• Revenues will not be sufficient to fund further development and clinical studies.
• Our ability to obtain necessary capital when needed on acceptable terms or at all.
• The Company may not meet its future capital requirements in different countries and municipalities.

Future Outlook

Fennec anticipates future launches of PEDMARQSI in other major European markets and expects to receive future commercial and regulatory milestone and royalty payments from Norgine.

Management Comments

• Jeff Hackman, chief executive officer of Fennec Pharmaceuticals, stated that there have been no pharmacological interventions available to cancer patients in Germany to prevent ototoxicity caused by cisplatin treatment until now.
• Jeff Hackman congratulated Norgine on making PEDMARQSI available to patients and healthcare providers in Germany and looks forward to future launches in other major European markets.

Industry Context

This announcement highlights the growing focus on supportive care in cancer treatment, specifically addressing the side effects of chemotherapy. The launch of PEDMARQSI addresses an unmet need for preventing hearing loss in pediatric cancer patients undergoing cisplatin treatment. This aligns with the broader industry trend of developing therapies that improve the quality of life for cancer survivors.

Comparison to Industry Standards

• PEDMARQSI's 50% reduction in ototoxicity in clinical trials compares favorably to the limited efficacy of cochlear implants, which are technically difficult and expensive.
• Unlike supportive care drugs from companies like Helsinn Healthcare SA, which focus on nausea and vomiting, PEDMARQSI targets a different and equally debilitating side effect of chemotherapy.
• The PUMA designation provides a competitive advantage similar to orphan drug status in the US, offering market exclusivity against potential competitors like Mylan or Teva who might develop generic versions of sodium thiosulfate.

Stakeholder Impact

• Shareholders can expect potential revenue growth and increased value from the commercialization of PEDMARQSI.
• Patients and healthcare providers in Germany now have access to a therapy to prevent cisplatin-induced ototoxicity.
• Employees of Fennec may benefit from the company's growth and success.

Next Steps

• Future launches of PEDMARQSI in other major European markets are anticipated.
• Fennec expects to receive future commercial and regulatory milestone and royalty payments from Norgine.

Key Dates

Keywords

PEDMARQSI, Fennec Pharmaceuticals, Norgine Pharmaceuticals, Ototoxicity, Cisplatin, Commercial Launch, Germany, Sodium Thiosulfate, Hearing Loss, Pediatric Cancer